The invention relates to an in-vitro method of diagnosis, prognosis,
treatment response control, response prediction, of a particular
human disease comprising the steps of: • (i) with one or more human samples, selected from the group comprising, a blood sample from a subject, a
plasma sample, a serum sample, a
urine sample, or a
buffy coat sample; • (ii) preparing a first and at least a second
nucleic acid sequencing
library from the nucleic acids present in said samples; • (iii) mixing the
nucleic acid sequencing libraries which were prepared to create a first mixed
nucleic acid sequencing
library (MNAL), • (iv) hybridizing one or more TAC oligonucleotides from a first TAC
oligonucleotide pool (TAC
oligonucleotide-1) to said first mixed nucleic acid
library (MNAL) thereby isolating a first subset of library nucleic acid molecules; • (v) sequencing said first subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a first group of putatively informative sequence variants (PISV 1); • (vi) hybridizing one or more TAC oligonucleotides from a second TAC
oligonucleotide pool comprising TAC oligonucleotides (TAC oligonucleotide-2) which are specific for the nucleic acid molecules of said first group of putatively informative sequence variants, to said first library of nucleic acid molecules thereby isolating a second subset of library nucleic acid molecules; • (vii) sequencing said second subset of library nucleic acid molecules and comparing the sequences determined to a human reference sequence, thereby creating a second group of putatively informative sequence variants (PISV2); • (viii) analyzing the putatively informative sequence variants (PISV2) thereby diagnosing, prognosing, controlling the response to a
drug, for a particular
human disease state.